Denali has cracked the blood–brain barrier in humans—AVLAYAH turns a risky platform bet into a first-mover CNS delivery franchise, with upside now hinging on launch execution and late-stage readouts.
Overview
Denali Therapeutics is a commercial-stage biotech built around solving the blood–brain barrier problem using its proprietary Transport Vehicle platform, which engineers biologics to leverage endogenous receptor pathways (notably transferrin receptor) to shuttle therapeutic payloads into the CNS. The investment profile shifted materially on March 25, 2026, when the FDA granted accelerated approval to AVLAYAH (tividenofusp alfa-eknm) for neurologic manifestations of Hunter syndrome—described as the first BBB-designed biologic approved for this setting and a pivotal validation of Denali’s platform thesis. Post-approval, Denali is transitioning from milestone-driven revenue to product-based specialty pharma revenue, recording initial product revenue beginning in Q2 2026, while still benefiting from strategic collaborations with partners such as Biogen, Sanofi, and Takeda (historically). Near-term focus is the U.S. ultra-orphan market where reimbursement dynamics are most supportive; medium-term growth includes EU regulatory filings and broader global expansion. Denali’s pipeline is organized by delivery modality (ETV/ATV/OTV) spanning rare pediatric lysosomal disorders and large neurodegenerative indications, with physician adoption driven by the key differentiator versus traditional therapies: whole-body treatment that addresses CNS decline rather than only peripheral symptoms. The report frames AVLAYAH as the de-risking event that converts Denali from a binary platform bet into a scalable CNS delivery company, while highlighting that success now hinges on launch execution, confirmatory data, and upcoming neurodegenerative readouts.